Segmed Highlights Evidence Gap in Radiology AI and Focus on Clinical Adoption

According to a recent LinkedIn post from Segmed, the current landscape of FDA-cleared radiology AI tools shows a significant evidence gap, with only 33 of 717 devices reportedly tested prospectively and 97% cleared via the 510(k) equivalence pathway. The post suggests that the main bottlenecks for adoption are not algorithms themselves, but clinical evidence, workflow integration, and trust at the point of care.

The post highlights an upcoming online event in Segmed’s “Bytes of Innovation” series on April 14, featuring George Harston, M.D., Ph.D., Chief Medical and Innovation Officer at Brainomix, and hosted by Segmed team members Aline Lutz, M.D., Ph.D., and Martin Willemink, M.D., Ph.D. The session is described as focusing on what is required for imaging AI to move from algorithm development to routine bedside use, and what lessons can be drawn from teams that have already navigated this path.

For investors, the emphasis on the gap between regulatory clearance and real-world clinical deployment points to a growing market niche around data quality, validation infrastructure, and post-market evidence generation in medical imaging AI. If Segmed is positioned as an enabler of rigorous clinical validation and workflow integration, increased attention to these issues could enhance its strategic relevance to AI developers, healthcare providers, and potential partners.

The educational format of the event also indicates an effort to build thought leadership and deepen relationships within the healthcare AI ecosystem, rather than promoting a specific product. Over time, stronger brand recognition among radiology AI stakeholders and alignment with quality and evidence-based deployment could support Segmed’s competitive position and create opportunities for revenue growth tied to data platforms, services, or collaborations in clinical AI.